This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.

Data-Driven Healthcare Disruptor Accolade Completes Successful IPO

Thinknum Media

Contributor:
Thinknum Media
Visit: Thinknum Media

By:

Associate Editor

If you want in, Accolade trades as $ACCD.

What does American Airlines ($NASDAQ:AAL), State Farm ($STATEFARM), Comcast ($NASDAQ:CMCSA), and Lowe’s ($NYSE:LOW) all have in common? They all rely on Accolade for healthcare access and benefits, and this has empowered the former startup to become a publicly-traded company over the weekend.

While everyone took Thursday off for the long holiday weekend, Accolade was ringing in their public debut and new stock ticker symbol $ACCD. “We’re changing the way healthcare works in this country,” CEO Rajeev Singh said to a mostly empty Times Square, in a pre-recorded message. He said of the co-founders, Tom Spann and Michael Cline, that they “said aloud something that most people in this country wholeheartedly agree with: healthcare is fundamentally broken. What made them different, like all great entrepreneurs, is that they set out to do something about it.” 

Accolade employee count on linkedin

The Seattle startup was founded in 2007 by Spann and Cline, and sought to use data-driven analytics, AI and machine learning, and cheaper costs to help usher in an era of “personalized healthcare advocacy.” A group of investors, including Andreessen Horowitz, agreed that this premise was the foundation of a good idea, and helped fund Accolade to the tune of $50 million in 2018

Accolade would have filed for its IPO back in February, but the coronavirus reared its ugly head and delayed everything. In the S-1 filing, the company said: “While the full effects of COVID-19 on the prospects of Accolade’s business are not yet known, we do know that we have served as a critical resource to our members during this difficult time.” 

“We believe our value proposition now resonates with an even broader audience of employers as they turn their focus to safely reopening their workplaces and managing the ongoing health and well-being of employees and their families,” the company added.

If you’re interested in the stock, it might help to know Accolade has 58 corporate clients so far, and has 1.7 million members actively. As long as healthcare can be disrupted by innovative startups like Accolade, these numbers might continue to grow, and we’ll continue tracking the data to find out what the future holds for the industry.

About the Data:

Thinknum tracks companies using the information they post online – jobs, social and web traffic, product sales, and app ratings – and creates data sets that measure factors like hiring, revenue, and foot traffic. Data sets may not be fully comprehensive (they only account for what is available on the web), but they can be used to gauge performance factors like staffing and sales.

Originally Posted on July 6, 2020 – Data-Driven Healthcare Disruptor Accolade Completes Successful IPO

Disclosure: Interactive Brokers

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Thinknum Media and is being posted with permission from Thinknum Media. The views expressed in this material are solely those of the author and/or Thinknum Media and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

trading top